Study of SPI-1620 in Combination With Docetaxel Versus Docetaxel Alone for Patients With Non Small-cell Lung Cancer (NSCLC)
The purpose of this study is to estimate and compare the objective response rate of SPI-1620 administered in combination with docetaxel in patients with NSCLC and to determine the safety of SPI-1620 when administered in combination with docetaxel.
Checked against the public recordLast updated Oct 13, 2021 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 2
- Sponsor
- Spectrum Pharmaceuticals, Inc
- Interventions being studied
- Drug: SPI-1620; Drug: Docetaxel
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Histologically or cytologically confirmed locally advanced or metastatic NSCLC that has failed one prior platinum-containing chemotherapy * Measurable disease as per RECIST v. 1.1 * Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 * Adequate bone marrow, liver and renal function Exclusion Criteria: * More than one prior chemotherapy regimen for metastatic NSCLC * Known, uncontrolled central nervous system (CNS) metastases * Significant circulatory disorders in the past 6 mo. * Concomitant treatment with phosphodiesterase inhibitors * Uncontrolled orthostatic hypotension, asthma or chronic obstructive pulmonary disease (COPD)
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Oncology Hematology Care Inc.Cincinnati, Ohio
- Tennessee Oncology PLLCChattanooga, Tennessee
- Tennessee OncologyNashville, Tennessee
- The Center for Cancer and Blood DisordersFort Worth, Texas
- Virginia Cancer InstituteRichmond, Virginia
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 13, 2021. Always confirm current availability with the study team.